id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-E-0133-0007,FDA,FDA-2011-E-0133,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2012-12-28T05:00:00Z,2012,12,2012-12-28T05:00:00Z,,2024-03-13T11:51:10Z,,0,0,090000648119d5e1
FDA-2011-E-0133-0006,FDA,FDA-2011-E-0133,Determinations of Regulatory Review Periods for Purposes of Patent Extensions: CYSVIEW (Previously HEXVIX),Notice,General Notice,2012-06-11T04:00:00Z,2012,6,2012-06-11T04:00:00Z,,2012-06-11T14:29:45Z,2012-14003,0,0,0900006481040a77
FDA-2011-E-0133-0005,FDA,FDA-2011-E-0133,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2012-06-04T04:00:00Z,2012,6,2012-06-04T04:00:00Z,,2024-03-13T12:18:04Z,,0,0,090000648102fdb6
FDA-2011-E-0133-0004,FDA,FDA-2011-E-0133,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2012-03-12T04:00:00Z,2012,3,2012-03-12T04:00:00Z,,2024-03-13T18:00:49Z,,0,0,0900006480fd39ae